Marketa Zvelebil | The Institute of Cancer Research (original) (raw)
Papers by Marketa Zvelebil
MOV file 2886K, Video showing dynamic flow adhesion assays of ZR75.1 shNTC and shST6 cells on a H... more MOV file 2886K, Video showing dynamic flow adhesion assays of ZR75.1 shNTC and shST6 cells on a HUVEC monolayer in the presence of the galectin-3 inhibitor GCS-100
MOV file 2346K, Video showing dynamic flow adhesion assays of ZR75.1 shNTC and shST6 cells on a H... more MOV file 2346K, Video showing dynamic flow adhesion assays of ZR75.1 shNTC and shST6 cells on a HUVEC monolayer
An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasi... more An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor gene Supplemental Material Supplementary Table S1. Primers and siRNAs Supplementary Figure S1. In vivo validation of shRNA screen hits Supplementary Figure S2. ST6GalNAc2 functions as a metastasis suppressor Supplementary Figure S3. Stable expression of ST6GalNAc2 in MDA-MB-231 cells Supplementary Figure S4. 4T1-Luc cell lung retention assays Supplementary Figure S5. Functional analysis of ST6GalNAc2 in human cell lines Supplementary Figure S6. Downregulation of ST6GalNAc2 promotes tumor cell aggregation in vivo Supplementary Movie S1. Dynamic flow adhesion assays on a HUVEC monolayer Supplementary Movie S2. Dynamic flow adhesion assays on a HUVEC monolayer in the presence of GCS-100
PDF file 299K, Additional characterization of human breast cancer cell lines; immunofluorescence ... more PDF file 299K, Additional characterization of human breast cancer cell lines; immunofluorescence analysis and lung retention assays
The promising antitumor activity of 17-allylamino-17-demethoxygeldanamycin (17AAG) results from i... more The promising antitumor activity of 17-allylamino-17-demethoxygeldanamycin (17AAG) results from inhibition of the molecular chaperone heat shock protein 90 (HSP90) and subsequent degradation of multiple oncogenic client proteins. Gene expression microarray and proteomic analysis were used to profile molecular changes in the A2780 human ovarian cancer cell line treated with 17AAG. Comparison of results with an inactive analogue and an alternative HSP90 inhibitor radicicol indicated that increased expression of HSP72, HSC70, HSP27, HSP47, and HSP90β at the mRNA level were on-target effects of 17AAG. HSP27 protein levels were increased in tumor biopsies following treatment of patients with 17AAG. A group of MYC-regulated mRNAs was decreased by 17AAG. Of particular interest and novelty were changes in expression of chromatin-associated proteins. Expression of the heterochromatin protein 1 was increased, and expression of the histone acetyltransferase 1 and the histone arginine methyltransferase PRMT5 was decreased by 17AAG. PRMT5 was shown to be a novel HSP90-binding partner and potential client protein. Cellular protein acetylation was reduced by 17AAG, which was shown to have an antagonistic interaction on cell proliferation with the histone deacetylase inhibitor trichostatin A. This mRNA and protein expression analysis has provided new insights into the complex molecular pharmacology of 17AAG and suggested new genes and proteins that may be involved in response to the drug or be potential biomarkers of drug action. [Cancer Res 2007;67(7):3239–53]